Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

C. Andrew Boswell, Eduardo E. Mundo, Crystal Zhang, +16

Bioconjugate Chemistry

NanotherapeuticsLocal PharmacologyImmunologyCellular PharmacologyPharmacotherapy +21

Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody–drug conjugates

Leanna R. Staben, Stefan G. Koenig, Sophie M. Lehar, +20

Nature Chemistry

Medicinal ChemistryAntibody–drug ConjugatesDrug TargetingMedicineTargeted Drug Delivery +6

Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody–Drug Conjugates

Niña G. Caculitan, Josefa Chuh, Yong Ma, +12

Cancer Research

Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering

Thomas H. Pillow, Janet Tien, Kathryn Parsons-Reponte, +24

Journal of Medicinal Chemistry

Discovery of Peptidomimetic Antibody–Drug Conjugate Linkers with Enhanced Protease Specificity

BinQing Wei, Janet Gunzner-Toste, Hui Yao, +30

Journal of Medicinal Chemistry

Peptide EngineeringImmunologyPeptide ScienceImmunotherapyEnhanced Protease Specificity +15

Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model

Cinthia V. Pastuskovas, Eduardo E. Mundo, Simon P. Williams, +21

Molecular Cancer Therapeutics

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Dongwei Li, Kirsten Achilles Poon, Shang‐Fan Yu, +25

Molecular Cancer Therapeutics

ImmunologyImmunotherapeuticsImmunotherapyTumor BiologyOncology +15

An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models

Suzie J. Scales, Nidhi Gupta, Glenn Pacheco, +14

Molecular Cancer Therapeutics

Antibody-drug Conjugate TherapyImmunologyImmunoeditingBiological TherapyImmunotherapeutics +17

<i>In vivo</i>effects of targeting CD79b with antibodies and antibody-drug conjugates

Bing Zheng, Reina N. Fuji, Kristi Elkins, +12

Molecular Cancer Therapeutics

Autoimmune DiseaseSystemic Lupus ErythematosusImmunologyB CellsPathology +13

A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

Neelie T. Zacharias, Vladimir N. Podust, Kimberly K. Kajihara, +38

Chemical Science